6,438
Total Publications
189,995
Total Citations
Top Researchers
- Li Zhang 57,567 citations • 2397 papers
- Wenxing Chen 56,471 citations • 699 papers
- Ling‐Ling Chen 42,021 citations • 313 papers
- Hui Li 38,697 citations • 3959 papers
- Liang Lin 34,817 citations • 860 papers
- Li Liu 34,158 citations • 1085 papers
- Yujie Chen 31,950 citations • 584 papers
- Jiansheng Li 31,551 citations • 988 papers
- Jing Sun 30,291 citations • 854 papers
- Yi Zheng 30,201 citations • 536 papers
Most Cited Papers
- SOAPnuke: a MapReduce acceleration-supported software for integrated quality control and preprocessing of high-throughput sequencing data 2017 • 2,488 citations
- Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries 2018 • 1,569 citations
- Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma 2021 • 778 citations
- First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study 2015 • 731 citations
- Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer 2019 • 700 citations
- WEGO 2.0: a web tool for analyzing and plotting GO annotations, 2018 update 2018 • 657 citations
- The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021 2021 • 648 citations
- Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study 2020 • 576 citations
- Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial 2022 • 547 citations
- Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study 2017 • 526 citations